|
|
|
|
||
Re: Big Q4 MilestoneFrom Exelixis web:''Under the terms of the Collaboration Agreement with Ipsen, Exelixis is eligible to receive a milestone payment of $40 million for the approval of the second-line treatment of HCC. This milestone would be paid by Ipsen within 70 days of the approval decision by the European Commission.'' |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
19656 | Re: Big Q4 Milestone | alias geo | 0 | 9/24/2018 10:10:39 PM |